FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
Syndicate content

saxagliptin news from FierceBiotech

News

FDA panel backs added risk review on diabetes drugs

A FDA advisory panel has voted 14-2 to recommend that the developers of diabetes drugs specifically demonstrate that their experimental therapies don't increase cardiovascular risks. And if as Read more...
Tags: Diabetes   saxagliptin  

DPP-4 inhibitors get spotlight at ADA meeting

Researchers are unveiling positive data at the American Diabetes Association's meeting for new DPP-4 inhibitors for diabetes. Takeda is the latest, demonstrating that its alogliptin can control blood Read more...

1. AstraZeneca and Bristol-Myers Squibb

Who: AstraZeneca  With: Bristol-Myers Squibb What: $1.05 billion collaboration Summary: In an unusual partnership between drug giants, AstraZeneca agreed to pay Bristol-Myers Squibb $100 million up Read more...